Description: Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Home Page: www.avacta.com
AVCT Technical Analysis
Thorp Arch Estate
Wetherby,
LS23 7FA
United Kingdom
Phone:
44 1904 217 070
Officers
| Name | Title |
|---|---|
| Dr. David Alastair Smith | CEO & Exec. Director |
| Mr. Tony Gardiner | CFO, Company Sec. & Exec. Director |
| Ms. Emma Wright | Group In-House Counsel |
| Mr. Michael Vinegrad | Group Communications Director |
| Dr. Matt Johnson | Chief Scientific Officer of Diagnostics |
| Dr. Neil Bell | Chief Devel. Officer of Therapeutics |
| Dr. Fiona McLaughlin FSB, Ph.D. | Chief Scientific Officer of Therapeutics Division |
| Mr. Marc Green | Head of Product Devel. - Diagnostics |
| Gemma Wilson | Head of QA/RA - Diagnostics |
| Mr. Petros Sarantos | Head of Product Management - Diagnostics |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.9049 |
| Price-to-Sales TTM: | 39.0603 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 133 |